Cingulate Inc.
CING- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001862150
No open-market purchases or sales by Cingulate Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $9.88M in total; no superinvestor holds it.
Other share classesCINGW
Q2 2022 vs. Q1 2022
How the institutions holding Cingulate Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 6 | 8 | +2 |
| Shares | 1.08M | 661.5K | −419.5K (−38.8%) |
| Value | $2.13M | $963.9K | −$1.17M (−54.7%) |
New holders (3)
Institutions that held Cingulate Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Creative Planning | 23,510 | $34.0K | 0.00% |
| StoneX Group Inc. | 15,000 | $21.9K | 0.00% |
| GoalVest Advisory LLC | 2,200 | $3.00K | 0.00% |
Sold out (1)
Institutions that held Cingulate Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Lynwood Capital Management Inc. | 225,994 | $445.0K |